$0.35
-0.0075[-2.10%]
Last update: 8:15AM Get Real Time Here
Mustang Bio
(NASDAQ:MBIO)Latest News for Mustang Bio Stock (NASDAQ:MBIO)
Mustang Bio Stock (NASDAQ: MBIO)
Categories: All
Thursday, April 18, 2024
Wednesday, April 17, 2024
Thursday, March 28, 2024
Monday, March 11, 2024
Thursday, March 07, 2024
- Why Rush Street Interactive Shares Are Trading Higher By Around 25%; Here Are 20 Stocks Moving PremarketAvi Kapoor - Mar 7, 2024, 8:05AM
- Phase 1 CAR T Cell Therapy Trial For Glioblastoma At City Of Hope, Demonstrates Clinical Activity Against Incurable Brain Tumors, The IL13Rα2-Targeting CAR T Cell Is Exclusively Licensed By Mustang Bio, A Fortress Biotech CompanyBenzinga Newsdesk - Mar 7, 2024, 5:06AM
Monday, December 11, 2023
Tuesday, November 14, 2023
Thursday, November 02, 2023
Thursday, October 26, 2023
- Why Harley-Davidson Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day SessionLisa Levin - Oct 26, 2023, 1:27PM
- Mustang Bio Announces $4.4M Registered Direct Offering Of 2,588,236 Of Its Shares Of Common Stock At A Price Of $1.70/Share, Priced At-the-Market Under Nasdaq RulesBenzinga Newsdesk - Oct 26, 2023, 12:31PM
- Mustang Bio shares are trading higher after the company announced the FDA accepted its IND application of MB-109 for the treatment of recurrent glioblastoma and high-grade astrocytoma.Benzinga Newsdesk - Oct 26, 2023, 12:04PM
- Mustang Bio Announces FDA Acceptance Of IND Application For MB-109, A Novel Combination Of MB-101 And MB-108, For The Treatment Of Recurrent Glioblastoma And High-Grade AstrocytomaBenzinga Newsdesk - Oct 26, 2023, 9:06AM
Thursday, September 21, 2023
Tuesday, September 19, 2023
Wednesday, August 16, 2023
- HC Wainwright & Co. Reiterates Buy on Mustang Bio, Maintains $25 Price TargetBenzinga Newsdesk - Aug 16, 2023, 11:59AM
- Mustang Bio Announces First Data From Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy; Iniital Data Show Clinical Responses From Four Of Four Indolent Lymphoma PatientsBenzinga Newsdesk - Aug 16, 2023, 8:03AM
Tuesday, August 15, 2023
- What 4 Analyst Ratings Have To Say About Mustang BioBenzinga Insights - Aug 15, 2023, 12:00PM
- BTIG Maintains Buy on Mustang Bio, Lowers Price Target to $16Benzinga Newsdesk - Aug 15, 2023, 11:32AM
- HC Wainwright & Co. Reiterates Buy on Mustang Bio, Maintains $25 Price TargetBenzinga Newsdesk - Aug 15, 2023, 6:35AM
Monday, August 14, 2023
Tuesday, July 11, 2023
- Runway Growth Finance Corp. Provides Second Quarter 2023 Portfolio UpdateHappy Mohamed - Jul 11, 2023, 8:53AM
- On July 10 Mustang Bio Terminated Exclusive License Agreement, Dated As Of March 17, 2017, By & Between Co & Regents Of University Of California; Will Not Incur Any Early Termination Penalties In Connection With Termination Of UCLA License AgreementHappy Mohamed - Jul 11, 2023, 8:09AM
Friday, June 16, 2023
- Why Mustang Bio's Stock Is Trading Higher TodayVandana Singh - Jun 16, 2023, 1:46PM
- BTIG Maintains Buy on Mustang Bio, Raises Price Target to $20Benzinga Newsdesk - Jun 16, 2023, 11:25AM
- HC Wainwright & Co. Reiterates Buy on Mustang Bio, Maintains $25 Price TargetBenzinga Newsdesk - Jun 16, 2023, 7:02AM
Wednesday, June 14, 2023
Thursday, May 18, 2023
- Mustang Bio Announces Manufacturing Partnership With uBriGene Under Which uBriGene Will Acquire Co.'s Worcester Manufacturing Facility For $11MBenzinga Newsdesk - May 18, 2023, 8:13AM
- uBriGene Biosciences To Acquire Mustang Bio's Worcester Manufacturing Facility For Up To $11M And Enters Into A Strategic Manufacturing Partnership To Support Mb-106 And Future PipelineBenzinga Newsdesk - May 18, 2023, 8:09AM
Monday, May 15, 2023
Friday, May 12, 2023
Thursday, May 11, 2023
Wednesday, April 05, 2023
Tuesday, April 04, 2023
Monday, April 03, 2023
Thursday, March 30, 2023
Monday, December 19, 2022
Wednesday, November 16, 2022
Monday, November 14, 2022
Wednesday, November 09, 2022
Thursday, October 27, 2022
- Mustang Bio Announces Phase 1/2 Clinical Trial Data Of MB-106, A First-in-Class CD20-targeted, Autologous CAR T Cell Therapy, To Be Presented At 11th International Workshop For Waldenstrom's MacroglobulinemiaBenzinga Newsdesk - Oct 27, 2022, 8:27AM
- 12 Health Care Stocks Moving In Thursday's Pre-Market SessionBenzinga Insights - Oct 27, 2022, 8:19AM